The prognostic value of myocardial myosin-binding protein C (cMyC) in acute myocardial infarction (AMI) remains insufficiently studied. To evaluate the association between admission cMyC levels and the risk of 30-day major adverse cardiovascular events (MACE) in patients with AMI. In this prospective, single-center study, patients with AMI admitted between March 2022 and July 2024 were included. cMyC and hs-cTnI were measured by point-of-care testing (POCT) at admission. The primary endpoint was 30-day MACE. Predictive performance was evaluated using ROC analysis and multivariable Cox regression. A total of 285 patients were included, with a 30-day MACE incidence of 27.4%. Admission cMyC was independently associated with 30-day MACE after adjustment for clinical covariates. Exploratory analyses suggested a graded association between cMyC levels and the risk of adverse outcomes. Admission cMyC measured by POCT was independently associated with 30-day MACE in patients with AMI. cMyC may serve as a rapid adjunctive biomarker for early risk stratification, although its incremental predictive value requires further validation.